Neoantigens for Personalized Cancer Vaccines: Comprehensive Identification and Effective Selection

Biomarkers, Drug Discovery and Development, Laboratory Technology, Life Sciences, Pharmaceutical,
  • Monday, June 18, 2018 | 1pm EDT (10am PDT)
  • 60 min

Developing effective personalized cancer vaccines depends on comprehensively detecting all neoantigens in a tumor sample and then selecting the neoantigens that are most likely to be effective in an individual patient. This process, especially under the timeline demands of clinical trials or commercial vaccine development, can be incredibly complex. Gaps in sequencing coverage found in standard exome and transcriptome assays can lead to missed neoantigens, and filtering neoantigens often requires incorporating data across multiple assays to make an informed decision.

Personalis developed the ACE ImmunoID platform to overcome these challenges. ACE ImmunoID combines augmented exome and transcriptome assays with advanced bioinformatics to both comprehensively identify neoantigens and provide accurate analytics to help inform the selection of candidate neoantigens.

Topics to be discussed during this webinar will include:

  • Technical overview of ACE ImmunoID including augmentation and validation
  • Review of bioinformatics deliverables and analytical modules including HLA Typing, Similarity-to-Self, Similarity-to-Known-Antigens, and Tumor Immunogenomics
  • Case study demonstrating ACE ImmunoID’s further utility in biomarker discovery through identifying methods of tumor escape in patients treated with checkpoint modulators
  • Best practices for designing rapid, patient-centric processes for vaccine clinical trials including optimizing sample preparation and integrating lab automation

Speakers

Sean Michael Boyle, MS, PhD, Director, Bioinformatics Applications, Personalis, Inc.

Sean is Director of Bioinformatics Applications at Personalis, with broad experience across analysis and interpretation of cancer genomics data. At Personalis, Sean leads a team focused on development in neoantigen prediction, cell free applications, tumor microenvironment analysis, and biomarker analysis for the ACE ImmunoID platform.  His team is also applying these technologies through external scientific collaborations with both academic and industry partners. Prior to Personalis, Sean worked on advancing genomics and personalized genomic medicine, notably with the Dr. Mike Snyder lab at Stanford University, where he developed novel methods for analyzing and interpreting patient samples from both cancer and inherited disease.

Message Presenter

Kedar Hastak, MS, PhD, Field Applications Scientist, Personalis, Inc.

Dr. Hastak is a Field Applications Scientist with ten years of basic and translational experience in cancer therapeutics. At Personalis, Kedar provides scientific technical support and customer education on the ACE Cancer Product Portfolio. Prior to joining Personalis, Kedar was a Senior Scientist at Stanford University’s Division of Oncology, where he led translational research studies to evaluate the efficacy of PARP inhibitors in treating breast and other solid tumor cancer models. He also was an instructor University of California, Berkeley. Kedar completed his postdoctoral studies at the Cleveland Clinic Foundation and Stanford University, and received his PhD in the field of Cancer Biology from Case Western Reserve University.

Message Presenter

Who Should Attend?

Professionals from biopharmaceutical organizations developing neoantigen-based therapeutics.

Relevant job functions include:

  • Heads of Immuno-Oncology Clinical Development Programs
  • Chief Medical and Scientific Officers
  • Biomarker Specialists
  • Translational Researchers
  • Regulatory Affairs

Relevant areas of interest include:

  • Immuno-oncology
  • Personalized medicines
  • Neoantigen-based therapeutics (vaccines, adoptive cell therapies)
  • Checkpoint inhibitors and immune modulators

What You Will Learn

  • Technical overview of ACE ImmunoID including augmentation and validation
  • Review of bioinformatics deliverables and analytical modules including HLA Typing, Similarity-to-Self, Similarity-to-Known-Antigens, Candidate Neoantigen Ranking, and Tumor Immunogenomics
  • Case study demonstrating ACE ImmunoID’s further utility in biomarker discovery through identifying methods of tumor escape in patients treated with checkpoint modulators
  • Best practices for designing rapid, patient-centric processes for vaccine clinical trials including optimizing sample preparation and integrating lab automation

Xtalks Partner

Personalis, Inc.

Personalis, Inc. is a provider of advanced genomic sequencing and analytics solutions to support the development of personal cancer vaccines and other next-generation cancer immunotherapies.

Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products. ACE Technology improves every individual step in the next-generation sequencing (NGS) process, from nucleic acid extraction, to sequencing assays, to data analytics. This makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions that are missed with the use of conventional sequencing techniques. Using this comprehensive approach, we provide genomic data of the highest quality and accuracy to help biopharma drive their immuno-oncology clinical and biomarker discovery programs, enabling the rational design and development of effective cancer immunotherapies.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account